Warp Sciences Funding History
Warp Sciences operates automated chemistry labs where robots synthesize and test compounds for drug discovery. The robots learn from demonstrations by human chemists.
Company Overview
Warp Sciences
San Francisco, California, US
Official WebsiteWarp Sciences Funding Timeline
Series A
US$215 million
Warp emerged from stealth to build a U.S. chemistry research service, initially focused on synthesizing variations of promising drug compounds.
Led by Lightspeed Venture Partners. Participation included Premji Invest, IVP, Lux Capital, Conviction, Menlo Ventures, Standard Capital, Lowercarbon Capital, Uncork Capital, Innovation Endeavors.
Source · businesswire.com ↗
Warp Sciences Founding Team
Warp Sciences brought together founders from AI research, public-sector data science, and medicinal chemistry. Their company uses automated labs to synthesize and test compounds for drug discovery.
- Kevin Weil — CEO. Former OpenAI Chief Product Officer and head of OpenAI for Science.
- DJ Patil — COO. Former first US Chief Data Scientist.
- Manohar Paluri — CTO. Former VP at Meta Superintelligence Labs and founding member of FAIR.
- Solomon Reisberg — CSO. Previously medicinal chemistry leadership at Terremoto Biosciences.
Warp Sciences Company Development
Teaching Robots to Carry Out Chemistry
At its public launch, Warp described U.S. chemistry labs that use human demonstrations to train robots to synthesize and test compounds. Its work turns an experimental procedure into something an automated lab can execute and repeat.
Warp Sciences Competitive Landscape
Executing Experiments After Choosing a Compound
Computational drug-discovery tools help decide which molecules might be worth making. Warp focuses on the next bottleneck: actually synthesizing and testing a compound in a physical lab. The two approaches can fit into the same research program.
